RV

Rohit Valecha

Active Director Director DIN 09204441
DIN 09204441 First appointment Jun 2021 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2021
Shareholding value •••• Premium profile

About Rohit Valecha

Data last updated:

Rohit Valecha is a Director at Adivis Pharma Private Limited (since 2021). The company operates in Chemicals. Adivis Pharma Private Limited reported revenue of ₹6.47 Cr (FY 2025).

DIN 09204441
Primary Designation Director
Industry Chemicals
First Appointment 15 Jun 2021
Oldest Company Age 5 yrs
Largest company Adivis Pharma Private Limited · ₹6.47 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Adivis Pharma Private Limited U24290DL2021PTC382288
Director15 Jun 20212021₹6.47 Cr (FY 2025)Active

Board colleagues of Rohit Valecha

NameDINCompanyDesignation
Lalit Wadhwa09204440Adivis Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Adivis Pharma Private Limited
Premium access

Shareholding and investment profile for Rohit Valecha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rohit Valecha

Rohit Valecha currently holds 1 directorship: Adivis Pharma Private Limited (Director, since 15 Jun 2021, revenue ₹6.47 Cr (FY 2025)).

Rohit Valecha was first appointed on 15 Jun 2021 as Director at Adivis Pharma Private Limited.

The current boards of Rohit Valecha's companies include Lalit Wadhwa (Adivis Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available